An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future

Ropeginterferon alfa-2b is a novel, long-acting mono-pegylated proline-IFN-alpha-2b approved for treatment of polycythemia vera in adults, regardless of thrombotic risk level or treatment history. Clinical trial data indicate the dose and titration of ropeginterferon alfa-2b is safe and effective. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Albert, Urbanski, Raymond W., Yu, Lennex, Ahmed, Tasfia, Mascarenhas, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913265/
https://www.ncbi.nlm.nih.gov/pubmed/36776307
http://dx.doi.org/10.3389/fonc.2023.1109866
_version_ 1784885383379550208
author Qin, Albert
Urbanski, Raymond W.
Yu, Lennex
Ahmed, Tasfia
Mascarenhas, John
author_facet Qin, Albert
Urbanski, Raymond W.
Yu, Lennex
Ahmed, Tasfia
Mascarenhas, John
author_sort Qin, Albert
collection PubMed
description Ropeginterferon alfa-2b is a novel, long-acting mono-pegylated proline-IFN-alpha-2b approved for treatment of polycythemia vera in adults, regardless of thrombotic risk level or treatment history. Clinical trial data indicate the dose and titration of ropeginterferon alfa-2b is safe and effective. However, additional studies may provide rationale for an amended, higher initial dosage and rapid titration. This article is an overview of current and upcoming studies of ropeginterferon alfa-2b in myeloproliferative neoplasms that support the exploration of an amended dosing scheme in order to optimize patient tolerability and efficacy outcomes.
format Online
Article
Text
id pubmed-9913265
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99132652023-02-11 An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future Qin, Albert Urbanski, Raymond W. Yu, Lennex Ahmed, Tasfia Mascarenhas, John Front Oncol Oncology Ropeginterferon alfa-2b is a novel, long-acting mono-pegylated proline-IFN-alpha-2b approved for treatment of polycythemia vera in adults, regardless of thrombotic risk level or treatment history. Clinical trial data indicate the dose and titration of ropeginterferon alfa-2b is safe and effective. However, additional studies may provide rationale for an amended, higher initial dosage and rapid titration. This article is an overview of current and upcoming studies of ropeginterferon alfa-2b in myeloproliferative neoplasms that support the exploration of an amended dosing scheme in order to optimize patient tolerability and efficacy outcomes. Frontiers Media S.A. 2023-01-19 /pmc/articles/PMC9913265/ /pubmed/36776307 http://dx.doi.org/10.3389/fonc.2023.1109866 Text en Copyright © 2023 Qin, Urbanski, Yu, Ahmed and Mascarenhas https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Qin, Albert
Urbanski, Raymond W.
Yu, Lennex
Ahmed, Tasfia
Mascarenhas, John
An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future
title An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future
title_full An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future
title_fullStr An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future
title_full_unstemmed An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future
title_short An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future
title_sort alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: an overview of previous and ongoing studies with perspectives on the future
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913265/
https://www.ncbi.nlm.nih.gov/pubmed/36776307
http://dx.doi.org/10.3389/fonc.2023.1109866
work_keys_str_mv AT qinalbert analternativedosingstrategyforropeginterferonalfa2bmayhelpimproveoutcomesinmyeloproliferativeneoplasmsanoverviewofpreviousandongoingstudieswithperspectivesonthefuture
AT urbanskiraymondw analternativedosingstrategyforropeginterferonalfa2bmayhelpimproveoutcomesinmyeloproliferativeneoplasmsanoverviewofpreviousandongoingstudieswithperspectivesonthefuture
AT yulennex analternativedosingstrategyforropeginterferonalfa2bmayhelpimproveoutcomesinmyeloproliferativeneoplasmsanoverviewofpreviousandongoingstudieswithperspectivesonthefuture
AT ahmedtasfia analternativedosingstrategyforropeginterferonalfa2bmayhelpimproveoutcomesinmyeloproliferativeneoplasmsanoverviewofpreviousandongoingstudieswithperspectivesonthefuture
AT mascarenhasjohn analternativedosingstrategyforropeginterferonalfa2bmayhelpimproveoutcomesinmyeloproliferativeneoplasmsanoverviewofpreviousandongoingstudieswithperspectivesonthefuture
AT qinalbert alternativedosingstrategyforropeginterferonalfa2bmayhelpimproveoutcomesinmyeloproliferativeneoplasmsanoverviewofpreviousandongoingstudieswithperspectivesonthefuture
AT urbanskiraymondw alternativedosingstrategyforropeginterferonalfa2bmayhelpimproveoutcomesinmyeloproliferativeneoplasmsanoverviewofpreviousandongoingstudieswithperspectivesonthefuture
AT yulennex alternativedosingstrategyforropeginterferonalfa2bmayhelpimproveoutcomesinmyeloproliferativeneoplasmsanoverviewofpreviousandongoingstudieswithperspectivesonthefuture
AT ahmedtasfia alternativedosingstrategyforropeginterferonalfa2bmayhelpimproveoutcomesinmyeloproliferativeneoplasmsanoverviewofpreviousandongoingstudieswithperspectivesonthefuture
AT mascarenhasjohn alternativedosingstrategyforropeginterferonalfa2bmayhelpimproveoutcomesinmyeloproliferativeneoplasmsanoverviewofpreviousandongoingstudieswithperspectivesonthefuture

Ejemplares similares